DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Ridker PM, MacFadyen JG, Everett BM. CANTOS Trial Group. et al.
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomized controlled trial.
Lancet 2018;
391: 319-328
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.